Postgraduate Base of the PLA Rocket Force Medical Center, Jinzhou Medical University, Jinzhou, 121001, Liaoning Province, China.
Department of Hepatobiliary Surgery, PLA Rocket Force Medical Center, Beijing, 100088, China.
J Cancer Res Clin Oncol. 2023 Jul;149(7):4015-4023. doi: 10.1007/s00432-022-04291-9. Epub 2022 Aug 29.
Repeat hepatectomy for adult recurrent hepatocellular carcinoma significantly prolongs the overall survival, but repeat hepatectomy for pediatric recurrent hepatoblastoma (HB) is rarely reported, and the outcomes are warranted to be investigated.
All patients between May 2015 and December 2020 with recurrent HB after intended surgical cure were retrospectively evaluated. Clinicopathologic features, surgical details and outcomes were analyzed during a median following-up of 24 months after repeat hepatectomy. Survival analysis was performed using the Kaplan-Meier estimate.
A total of 18 patients of recurrent HB undergoing repeat hepatectomy with radical cure intention were included. There were 11 males and 7 females. The median age was 29 months (range 5-87 months) at first hepatectomy, and the median time to the recurrence from the first hepatectomy was 7 months. The operating time of the repeat hepatectomy was 5.0 h (range 3.5-9.0 h) and the mean blood loss was 592 ml (range 50-3200 ml). Radical resection (R0) was achieved in 12 patients (66.7%), with a postoperative hospital stay of 7.9 ± 1.8 days. No serious postoperative complications or mortality occurred. The overall survival (OS) rate was 55.6% (10/18) and the event-free survival (EFS) rate was 33.3% (6/18). Those with no lung metastases, not high-risk stratification, and achieving R0 hepatectomy, anatomic hepatectomy had longer OS rate (all P < 0.05) after repeat hepatectomy. Two of three patients with re-recurrence HB undergoing salvage liver transplantation were alive with a tumor-free survival.
Repeat hepatectomy for recurrent HB can be carried out safely. However, only a highly selected subgroup of patients might actually benefit from this procedure.
成人复发性肝细胞癌再次肝切除可显著延长总生存期,但儿童复发性肝母细胞瘤(HB)再次肝切除的报道很少,其结果尚待研究。
回顾性分析 2015 年 5 月至 2020 年 12 月间,计划手术治愈后复发的 HB 患儿,分析其临床病理特征、手术细节和结果,中位随访时间为再次肝切除后 24 个月。采用 Kaplan-Meier 估计进行生存分析。
共纳入 18 例复发性 HB 患儿行根治性再次肝切除术。男 11 例,女 7 例。首次肝切除时中位年龄 29 个月(5-87 个月),首次肝切除后中位复发时间为 7 个月。再次肝切除术的手术时间为 5.0 小时(3.5-9.0 小时),平均失血量为 592ml(50-3200ml)。12 例(66.7%)患者达到根治性切除(R0),术后住院时间为 7.9±1.8 天。无严重术后并发症或死亡。总生存期(OS)率为 55.6%(10/18),无事件生存率(EFS)率为 33.3%(6/18)。无肺转移、非高危分层、达到 R0 肝切除、解剖性肝切除的患者,再次肝切除后 OS 率较高(均 P<0.05)。3 例复发性 HB 再次复发患者中的 2 例接受挽救性肝移植,肿瘤无进展生存。
复发性 HB 再次肝切除是安全的,但只有一小部分高度选择的患者可能真正受益于该手术。